Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report.

JTO clinical and research reports·2026
Same author

Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.

Transplantation and cellular therapy·2026
Same author

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Intensive care medicine·2026
Same author

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

International journal of cancer·2026
Same author

The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).

International journal of cancer·2026
Same author

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

Blood advances·2026
Same journal

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Oncoimmunology·2026
Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026
Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026
Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026
Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026
Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Engineering effective T-cell based antitumor immunity.

Thomas Gruber1, Reinhard Hinterleitner, Christa Pfeifhofer-Obermair

  • 1Department of Pharmacology and Genetics; Medical University Innsbruck; Innsbruck, Austria.

Oncoimmunology
|March 26, 2013
PubMed
Summary
This summary is machine-generated.

Depleting CBLB in T cells enhances their effectiveness as an adjuvant for dendritic cell (DC) vaccination. This strategy shows promise for improving adoptive cell therapy outcomes.

Keywords:
RNA interferencecancer immunotherapycblbengineered T cellsreinforced anti-tumor functions

More Related Videos

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Area of Science:

  • Immunology
  • Cell Therapy
  • Molecular Biology

Background:

  • Adoptive cell therapy (ACT) shows promise but often requires adjuvants to enhance efficacy.
  • Dendritic cell (DC) vaccination is a strategy to stimulate anti-tumor immunity.
  • Cereblon E3 ubiquitin ligase (CBLB) is an endogenous inhibitor of T cell receptor (TCR) signaling.

Purpose of the Study:

  • To investigate the potential of CBLB inhibition to enhance the adjuvant properties of CD8+ T cells for DC vaccination.
  • To evaluate the therapeutic benefit of using CBLB-depleted autologous CD8+ T cells in combination with DC vaccination.

Main Methods:

  • Generation of autologous CD8+ T cells with CBLB depletion using small interfering RNA (siRNA).
  • Assessment of the adjuvant effect of these modified T cells in a DC vaccination model.
  • Evaluation of therapeutic outcomes in relevant models.

Main Results:

  • Synthetic siRNA-mediated CBLB depletion effectively reduced CBLB expression in CD8+ T cells.
  • CBLB-depleted CD8+ T cells demonstrated enhanced adjuvant capacity for DC vaccination.
  • The combined approach provided significant therapeutic benefits.

Conclusions:

  • Inhibiting CBLB in adoptively transferred CD8+ T cells augments their function as an adjuvant.
  • This strategy represents a rational approach to improve the effectiveness of cell-based immunotherapies.
  • Targeting CBLB offers a novel avenue for enhancing adoptive immune cell therapies.